TRIUMPH program trial design overview — all Phase 3 arms
Posting this as an important update for the retatrutide & triple agonists community. Please read carefully as this may affect your current plans.
I will keep this thread updated as new information becomes available. If you have additional information or corrections, please post below and I will incorporate confirmed updates into this OP.
Key points:
- This information is current as of the date posted
- Circumstances may change — always verify independently
- If you have questions, check if they have been answered in the replies before posting
Bookmarking this thread is recommended — it will be updated as the situation evolves.
TrialTracker_MD said:TRIUMPH program trial design overview — all Phase 3 arms Posting this as an important update for the retatrutide & triple agonists community.
Fair, but phase 2 tolerability figures rarely survive contact with phase 3 scale. Triple agonism means three receptor systems generating adverse events, and the dropout column is the one I would read first when the larger trials report.
TrialTracker_MD said:TRIUMPH program trial design overview — all Phase 3 arms Posting this as an important update for the retatrutide & triple agonists community.
I would rather people stopped quoting the 24% as if it were a licensed outcome. It is a phase 2 result in a few hundred participants with no cardiovascular endpoint and no long-term safety data, and this board has a habit of treating pipeline numbers as settled.
Janoshik Analytical — Independent Testing
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesGL Biochem (Shanghai) Ltd. — Direct Manufacturer
Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL BiochemAnswering the narrow version, because the broad one does not have a single answer. The glucagon component looks paradoxical and is not. Glucagon receptor agonism raises energy expenditure and drives hepatic fatty-acid oxidation, and its hyperglycaemic tendency is offset by the GLP-1 arm's insulin secretagogue effect. Net result: intake down from GLP-1/GIP, expenditure up from glucagon, glycaemia neutral or improved. It is a balancing act, and it is why the liver-fat results are the most interesting part of the dataset.
Dr.NutriCornell said:Fair, but phase 2 tolerability figures rarely survive contact with phase 3 scale.
Agreed, and subgroup analyses deserve particular suspicion. With enough subgroups something is significant by chance, and pre-registered subgroups are a different animal from ones found afterwards.
If somebody has the primary source to hand I would rather cite it than paraphrase it.